Revisional Notes on the Cloud Forest Butterfly Genus Oxeoschistus Butler in Central America (Lepidoptera: Nymphalidae: Satyrinae).

So far, six species of Oxeoschistus Butler, including its junior synonym Dioriste Thieme, were listed from Central America, with five of them from Costa Rica alone, which appears to represent the highest regional diversity of this Neotropical montane butterfly genus. Our research based on field work, morphological studies and barcode analysis proved that one record is a misunderstanding perpetuated in scientific literature for over a century: Oxeoschistus cothonides Grose-Smith is identified here as an individual form of the female of O. cothon Salvin. The presence of Oxeoschistus tauropolis (Westwood) in Costa Rica, subject to some controversy, is confirmed, and a new local subspecies is described from Costa Rica, O. tauropolis mitsuko Pyrcz & Nakamura n. ssp. Specific status of O. euriphyle Butler is reinstated based on morphological and molecular data. A new subspecies O. hilara lempira Pyrcz n. ssp. is described from Honduras. O. puerta submaculatus Butler is reported for the first time from the Darién region on the Panama-Colombia border. Species relationships are preliminarily evaluated based on COI data concluding, among others, that O. hilara and O. euriphyle are less closely related than previously assumed. Altitudinal and distributional data are revised, and ecological and behavioural information of all the species of Central American Oxeoschistus is provided.

Intratumor chemotherapy in combination with a systemic antimetastatic drug in the treatment of Lewis-lung carcinoma.

The effect of an antimetastatic agent plus intratumor chemotherapy was evaluated in mice bearing Lewis-lung carcinoma by measuring survival time and by histological examination. Polymeric flavan-3,4-diol (APF) from avocado seeds, Persea gratissima, administered alone directly into the tumor did not change survival time, although it partially destroyed the primary tumor. However, the drug administered in combination with an antimetastatic, 1,2-bis(3,5-dioxopiperazin-1-yl)ethane (ICRF-154), resulted in an increase in survival time. When 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) was used in place of polymeric flavanadiol as an intralesional drug, a significant increase in survival was also achieved. The effect of each drug alone and of their combination was evaluated by "responder analyses". Animals "cured" by the combination and rechallenged with 2 X 10(6) tumor cells showed that immunization could occur.